NCT00684710已完成1 期
Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 56 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 56
- 主要终点
- Safety and Tolerability
研究概览
简要总结
This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of PAZ-417 after administration of ascending single oral doses to healthy young Japanese male and healthy elderly Japanese male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
PAZ-417
Experimental
干预措施: PAZ-417 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Safety and Tolerability
时间窗: 3 months
次要结局
- Pharmacokinetics(3 months)
研究者
相似试验
已完成
1 期
Study Evaluating the Safety, Tolerability and Pharmacokinetics of NSA-789 in Healthy Japanese Male SubjectsHealthyNCT00619736Wyeth is now a wholly owned subsidiary of Pfizer56
已完成
1 期
Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy SubjectsHealthyNCT00550381Wyeth is now a wholly owned subsidiary of Pfizer72
终止
1 期
Study Evaluating FXR-450 in Healthy Japanese MenHealthyNCT00509756Wyeth is now a wholly owned subsidiary of Pfizer56
已完成
1 期
Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257Healthy SubjectsNCT00722501Wyeth is now a wholly owned subsidiary of Pfizer48
已完成
1 期
Study Evaluating The SBI-087 In Subjects With Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT00714116Pfizer30